LB Pharmaceuticals Inc Common Stock
LBRXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | Sumant Kulkarni | $65.00(+88%) | $34.61 | TheFly |
| Oct 5, 2026 | Guggenheim | $80.00(+131%) | $34.62 | TheFly | |
| Oct 5, 2026 | Roth Capital | $35.00(-3%) | $35.95 | TheFly | |
| Oct 2, 2026 | Needham | $68.00(+82%) | $37.28 | TheFly | |
| Aug 24, 2026 | H.C. Wainwright | Raghuram Selvaraju | $60.00(+26%) | $47.62 | TheFly |
| Aug 13, 2026 | Stifel Nicolaus | $53.00(+17%) | $45.38 | TheFly | |
| Aug 12, 2026 | BMO Capital | $54.00(+19%) | $45.33 | TheFly | |
| Aug 3, 2026 | Piper Sandler | Yasmeen Rahimi | $78.00(+81%) | $43.14 | StreetInsider |
| Jul 20, 2026 | BMO Capital | $46.00(+49%) | $30.90 | TheFly | |
| Jul 7, 2026 | Wolfe Research | Rudy Li | $45.00(+35%) | $33.41 | TheFly |
| May 17, 2026 | Roth Capital | $37.00(+25%) | $29.66 | TheFly | |
| Apr 27, 2026 | H.C. Wainwright | $45.00(+46%) | $30.73 | TheFly | |
| Apr 10, 2026 | Craig-Hallum | $36.00(+46%) | $24.68 | TheFly | |
| Mar 27, 2026 | Stifel Nicolaus | $40.00(+68%) | $23.84 | TheFly | |
| Jan 9, 2026 | Roth Capital | $31.00(+49%) | $20.80 | TheFly | |
| Dec 11, 2025 | Stifel Nicolaus | $35.00(+64%) | $21.36 | TheFly | |
| Oct 6, 2025 | Leerink Partners | $34.00(+126%) | $15.05 | TheFly | |
| Oct 6, 2025 | Stifel Nicolaus | $27.00(+79%) | $15.05 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Roth Capital | downgrade | Buy →Neutral | Oct 5, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 24, 2026 |
| BMO Capital | maintain | Outperform | Aug 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 3, 2026 |
| Stifel | maintain | Buy | Mar 27, 2026 |
| Stifel | maintain | Buy | Dec 11, 2025 |
Earnings History
Next report: Mar 25, 2027 · EPS est. $-1.64| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-1.79 | $-1.62 | — | — |
| Aug 11, 2026 | $-1.71 | $-0.80 | — | — |
| May 12, 2026 | $-0.67 | $-0.75 | — | — |
| Mar 26, 2026 | $-0.45 | $-0.45 | — | — |
| Nov 6, 2025 | $-0.61 | $-0.57 | — | — |
| Sep 8, 2025 | $-1.44 | — | — | — |
News
I build my biotech investments using technical analysis, focusing on price action and volume, not traditional fundamentals. I target small-cap biotechs advancing past Phase 2, especially those addressing hard-to-treat diseases with novel approaches. Recent regulatory headwinds have eased, derisking select names and enabling ground-floor entry after a sector-wide sell-off.
Strengthened leadership with the appointment of Susan G. Kozauer, M.D.
LB Pharmaceuticals NASDAQ: LBRX outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The company said it expects three clinical readouts over the next three years, beginning with Phase III schizophrenia data in the first half of 2027.
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. The event will feature Roger S.
LB Pharmaceuticals Inc (NASDAQ: LBRX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has
LB Pharmaceuticals earns a buy rating, with a base case valuation of $85 per share and potential upside to $150 if Phase 3 and clinical differentiation succeed. LB-102's N-methyl modification enables effective brain receptor occupancy at much lower doses than amisulpride, supporting once-daily dosing and potentially fewer side effects. The main investment debate centers on whether the R-enantiomer's 5-HT7 activity delivers unique clinical benefits beyond D2/D3 antagonism, which remains unproven.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G.
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer.
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expa…